{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:01:08Z","timestamp":1794326468321,"version":"4.9.0"},"reference-count":286,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T00:00:00Z","timestamp":1327363200000},"content-version":"vor","delay-in-days":10427,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1983,7,8]]},"abstract":"<jats:p>Labetalol is a combined alpha\u2010 and beta\u2010adenoceptor blocking agent for oral and intravenous use in the treatment of hypertension. It is a nonselective competitive antagonist at beta\u2010adrenoceptors and a competitive antagonist of postsynaptic alpha<jats:sub>1<\/jats:sub>\u2010adrenoceptors. Labetalol is more potent at beta than at alpha<jats:sub>1<\/jats:sub> adrenoceptors in man; the ratio of beta\u2010alpha antagonism is 3:1 after oral and 6.9:1 after intravenous administration.<\/jats:p><jats:p>Labetalol is readily absorbed in man after oral administration, but the drug, which is lipid soluble, undergoes considerable hepatic first\u2010pass metabolism and has an absolute bioavailability of approximately 25%. There are no active metabolites, and the elimination half\u2010life of the drug is approximately 6 hours.<\/jats:p><jats:p>Unlike conventional beta\u2010adrenoceptor blocking drugs without intrinsic sympathomimetic activity, labetalol, when given acutely, produces a decrease in peripheral vascular resistance and blood pressure with little alteration in heart rate or cardiac output. However, like conventional beta\u2010blockers, labetalol may influence the renin\u2010angiotensin\u2010aldosterone system and respiratory function.<\/jats:p><jats:p>Clinical studies have shown that the antihypertensive efficacy of labetalol is superior to placebo and to diuretic therapy and is at least comparable to that of conventional beta\u2010blockers, methyldopa, clonidine and various adrenergic neuronal blockers. Labetalol administered alone or with a diuretic is often effective when other antihypertensive regimens have failed. Studies have shown that labetalol is effective in the treatment of essential hypertension, renal hypertension, pheochromocytoma, pregnancy hypertension and hypertensive emergencies. In addition, preliminary studies indicate that labetalol may be of value in the management of ischemic heart disease.<\/jats:p><jats:p>The most troublesome side effect of labetalol therapy is posture\u2010related dizziness. Other reported side effects of the drug include gastrointestinal disturbances, tiredness, headache, scalp tingling, skin rashes, urinary retention and impotence. Side effects related to the beta\u2010adrenoceptor blocking effect of labetalol, including asthma, heart failure and Raynaud's phenomenon, have been reported in rare instances.<\/jats:p>","DOI":"10.1002\/j.1875-9114.1983.tb03252.x","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T19:31:21Z","timestamp":1450294281000},"page":"193-217","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":155,"title":["Labetalol: A Review of Its Pharmacology, Pharmacokinetics, Clinical Uses and Adverse Effects"],"prefix":"10.1002","volume":"3","author":[{"given":"E. Paul","family":"MacCarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul S.","family":"Bloomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1982.tb09275.x"},{"issue":"3","key":"e_1_2_1_3_2","first-page":"681","volume":"3","author":"Labetalol Symposium.","year":"1976","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"e_1_2_1_4_2","first-page":"S89","volume":"8","author":"Proceedings of the second labetalol symposium.","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01883.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198100031-00001"},{"issue":"2","key":"e_1_2_1_7_2","first-page":"1","article-title":"Combined alpha\u2010 and beta\u2010adrenoceptor blockade with labetalol","volume":"56","year":"1980","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1972.tb08125.x"},{"issue":"3","key":"e_1_2_1_9_2","first-page":"681","article-title":"A review of the animal pharmacology of labetalol, a combined \u03b1\u2010 and \u03b2\u2010adrenoceptor\u2010blocking drug","volume":"3","author":"Brittain RT","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(78)90024-1"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.74.819"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0022-3565(25)32689-3","article-title":"Alpha and beta adrenoceptor blocking properties of labetalol and its R,R\u2010isomer, SCH19927","volume":"218","author":"Sybertz EJ","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1979.tb13663.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1979.tb16100.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0022-3565(25)32690-X","article-title":"Antihypertensive and hemodynamic actions of SCH19927, the R,R\u2010isomer of labetalol","volume":"218","author":"Baum T","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1977.tb07733.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1975.tb07398.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006193022504"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(77)90066-2"},{"key":"e_1_2_1_20_2","first-page":"325","volume-title":"Pharmacology of antihypertensive agents","author":"Levy GP","year":"1980"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(77)90351-X"},{"key":"e_1_2_1_22_2","first-page":"59","volume-title":"Presynaptic receptors","author":"Drew GM","year":"1979"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1978.tb17303.x"},{"key":"e_1_2_1_24_2","first-page":"468P","article-title":"Pharmacological characterization of \u03b1\u2010adrenoceptors which mediate clonidine\u2010induced sedation (abstract)","volume":"61","author":"Drew GM","year":"1977","journal-title":"Br J Pharmacol"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198107000-00015"},{"key":"e_1_2_1_26_2","first-page":"229","volume-title":"Pharmacological and biochemical properties of drug substances","author":"Brittain RT","year":"1979"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00508278"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(78)90417-X"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/10641967909068627"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(77)90265-9"},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0022-3565(25)29938-4","article-title":"Release of norepinephrine and dopamine\u2010\u03b2\u2010hydroxylase by nerve stimulation. I. Role of neuronal and extraneuronal uptake and presynaptic alpha receptors","volume":"190","author":"Cubeddu XL","year":"1974","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1978233253"},{"key":"e_1_2_1_33_2","first-page":"1049","article-title":"Antihypertensive effects of labetalol (SCH 15719W, AH 5158A) (abstract)","volume":"36","author":"Johnson GL","year":"1977","journal-title":"Fed Proc"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1980.tb07934.x"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/16.5.233"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/16.7.398"},{"issue":"3","key":"e_1_2_1_37_2","first-page":"711","article-title":"Affinity of labetalol for ocular melanin","volume":"3","author":"Poynter D","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_38_2","first-page":"58","volume-title":"Investigator's brochure on labetalol (intravenous and oral): alpha\u2010beta adrenoceptor blocking agent","author":"Schering\u2010Plough Research Division.","year":"1978"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00562897"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198104000-00008"},{"key":"e_1_2_1_41_2","first-page":"160","article-title":"An HPLC assay for labetalol in human plasma using PRP\u20101 column and fluorometric detection (abstract)","volume":"12","author":"Alton K","year":"1982","journal-title":"Am Pharm Assoc Acad Pharmaceut Sci"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(00)86420-1"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0160-5402(81)90070-X"},{"issue":"3","key":"e_1_2_1_44_2","first-page":"695","article-title":"Metabolism of labetalol by animals and man","volume":"3","author":"Martin LE","year":"1976","journal-title":"Br J Clip Pharmacol"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04773.x"},{"key":"e_1_2_1_46_2","first-page":"1557","article-title":"Bioavailability\/pharmacokinetics of labetalol in normotensive male volunteers (abstract)","volume":"41","author":"Leitz F","year":"1982","journal-title":"Fed Proc"},{"key":"e_1_2_1_47_2","first-page":"39","article-title":"Multiple\u2010dose pharmacokinetics of labetalol in hypertensive patients (abstract)","volume":"12","author":"Chung M","year":"1982","journal-title":"Am Pharm Assoc Acad Pharmaceut Sci"},{"key":"e_1_2_1_48_2","first-page":"41","article-title":"Pharmacokinetics of labetalol in healthy volunteers","volume":"19","author":"Kanto J","year":"1981","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb01076.x"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb04936.x"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)92903-2"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01983.x"},{"issue":"665","key":"e_1_2_1_53_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.0954-6820.1982.tb00422.x","article-title":"Treatment of hypertension in the elderly with labetalol","author":"Eisalo A","year":"1982","journal-title":"Acta Med Scand"},{"key":"e_1_2_1_54_2","unstructured":"ChungM LeitzF MaierGet al.Rising multiple dose study of labetalol in hypertensive patients; pharmacokinetic profile (abstract). Presented at II World Conference on Clinical Pharmacology and Therapeutics Washington D.C.July 31August 5 1983."},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1981.tb13743.x"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6144.1048"},{"key":"e_1_2_1_57_2","first-page":"287","article-title":"Labetalol used as a hypotensive agent in the presence of renal disease (abstract)","volume":"11","author":"Thompson FD","year":"1977","journal-title":"Kidney Int"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01893.x"},{"issue":"665","key":"e_1_2_1_59_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.0954-6820.1982.tb00423.x","article-title":"Labetalol in the treatment of hypertension in patients with normal and impaired renal function","author":"Walstad RA","year":"1982","journal-title":"Acta Med Scand"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04770.x"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04768.x"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb00916.x"},{"key":"e_1_2_1_63_2","first-page":"438","article-title":"The hypotensive effect of a single daily dose of labetalol: a preliminary study","volume":"20","author":"Rossi A","year":"1982","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04765.x"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04766.x"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1982.tb03824.x"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01886.x"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198100031-00005"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01887.x"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6134.383"},{"key":"e_1_2_1_71_2","unstructured":"GuralRP LeitzF PatrickJet al.Rising multiple dose study of labetalol in hypertensive patients; pharmacodynamic profile (abstract). Presented at II World Conference on Clinical Pharmacology and Therapeutics Washington D.C.July 31August 5 1983."},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01892.x"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04772.x"},{"issue":"3","key":"e_1_2_1_74_2","first-page":"799","article-title":"Effect on blood pressure, angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol","volume":"3","author":"Trust PM","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_75_2","first-page":"497s","article-title":"Effects of intravenous labetalol on blood pressure, angiotensin II and aldosterone in hypertension: comparison with propranolol","volume":"51","author":"Rosei EA","year":"1976","journal-title":"Clin Sci Mol Med"},{"issue":"3","key":"e_1_2_1_76_2","first-page":"789","article-title":"Acute hemodynamic effects of labetalol and its subsequent use as an oral hypotensive agent","volume":"3","author":"Joekes AM","year":"1976","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"e_1_2_1_77_2","first-page":"721","article-title":"Pharmacological effects of labetalol in man","volume":"3","author":"Richards DA","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1972.tb07265.x"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1978243264"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1974.tb01702.x"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.39.1.99"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb05849.x"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1976.tb00637.x"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1983.33"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb00948.x"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb01665.x"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(66)90061-0"},{"key":"e_1_2_1_88_2","first-page":"389P","article-title":"Modification of pressor responses induced by \u201ccold\u201d (abstract)","volume":"4","author":"Maconochie JG","year":"1977","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6017.1046"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.55.2.370"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04762.x"},{"issue":"2","key":"e_1_2_1_92_2","first-page":"21","article-title":"Sequential haemodynamic effects of labetalol at rest and during exercise in essential hypertension","volume":"56","author":"Svendsen TL","year":"1980","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_93_2","first-page":"97s","article-title":"Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydralazine, and diazoxide: the use of AH 5158 in the treatment of hypertension","volume":"48","author":"Prichard BNC","year":"1975","journal-title":"Clin Sci Mol Med"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04764.x"},{"issue":"2","key":"e_1_2_1_95_2","first-page":"37","article-title":"Immediate effects of labetalol on central, splanchnic\u2010hepatic, and forearm haemodynamics during pleasant emotional stress in hypertensive patients","volume":"56","author":"Trap\u2010Jensen J","year":"1980","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01894.x"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1983.21"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04763.x"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01884.x"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00605625"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01223.x"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01946.x"},{"issue":"2","key":"e_1_2_1_103_2","first-page":"17","article-title":"Immediate haemodynamic and metabolic effects of intravenous labetalol in the exercising forearm","volume":"56","author":"Hartling OJ","year":"1980","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.285.6338.325"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(82)90054-6"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01897.x"},{"issue":"3","key":"e_1_2_1_107_2","first-page":"733","article-title":"Haemodynamic effects of long\u2010term oral labetalol","volume":"3","author":"Edwards RC","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.60.6.1214"},{"issue":"665","key":"e_1_2_1_109_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.0954-6820.1982.tb00415.x","article-title":"Effects of labetalol and propranolol on the peripheral circulation in hypertensive patients","author":"Nyberg G","year":"1982","journal-title":"Acta Med Scand"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb00991.x"},{"issue":"3","key":"e_1_2_1_111_2","first-page":"729","article-title":"Combined \u03b1\u2010 and \u03b2\u2010adrenoceptor blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise","volume":"3","author":"Koch G","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-197911000-00003"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(78)90017-6"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs057401s"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb05813.x"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1978.tb04847.x"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198011000-00005"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00605626"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04719.x"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6103.1673-a"},{"key":"e_1_2_1_121_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6140.800"},{"key":"e_1_2_1_122_2","first-page":"317","article-title":"Urinary catecholamines and labetalol","volume":"236","author":"Preziosi P","year":"1978","journal-title":"Arch Int Pharmacodyn"},{"key":"e_1_2_1_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(79)90361-9"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6164.685-c"},{"key":"e_1_2_1_125_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01477140"},{"key":"e_1_2_1_126_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6158.268-d"},{"issue":"2","key":"e_1_2_1_127_2","first-page":"49","article-title":"Plasma catecholamines, renin and aldosterone during combined alpha\u2010 and beta\u2010adrenoceptor blockade in patients with severe arterial hypertension","volume":"56","author":"Kornerup HJ","year":"1980","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_128_2","first-page":"337A","article-title":"Disproportionate increase in plasma norepinephrine concentration during labetalol\u2010induced vasodepression (abstract)","volume":"30","author":"Lin MS","year":"1982","journal-title":"Clin Res"},{"key":"e_1_2_1_129_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00560454"},{"issue":"2","key":"e_1_2_1_130_2","first-page":"43","article-title":"Effect of labetalol on plasma catecholamines at rest and during increased sympathetic activity","volume":"56","author":"Carlsen JE","year":"1980","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_131_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198109000-00008"},{"issue":"3","key":"e_1_2_1_132_2","first-page":"757","article-title":"Antihypertensive action, time of onset and effects on carbohydrate metabolism of labetalol","volume":"3","author":"Andersson O","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_133_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1982.tb03178.x"},{"key":"e_1_2_1_134_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb04968.x"},{"key":"e_1_2_1_135_2","first-page":"379","article-title":"The effects of labetalol and oxprenolol on blood lipids","volume":"60","author":"Sommers DEK","year":"1981","journal-title":"S Afr Med J"},{"key":"e_1_2_1_136_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-6989(79)80084-3"},{"key":"e_1_2_1_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)90759-5"},{"key":"e_1_2_1_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(82)92343-8"},{"key":"e_1_2_1_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(83)80081-2"},{"key":"e_1_2_1_140_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1977.tb00660.x"},{"key":"e_1_2_1_141_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1977.tb00688.x"},{"key":"e_1_2_1_142_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01855.x"},{"issue":"3","key":"e_1_2_1_143_2","first-page":"795","article-title":"Intravenous labetalol in hypertensive patients treated with \u03b2\u2010adrenoceptor blocking drugs","volume":"3","author":"Pearson RM","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_144_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1977.tb00736.x"},{"key":"e_1_2_1_145_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5962.59"},{"key":"e_1_2_1_146_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb02089.x"},{"issue":"8","key":"e_1_2_1_147_2","first-page":"1419","article-title":"Labetalol, beta blockers and acute deterioration of chronic airway obstruction","volume":"4","author":"Adam WR","year":"1982","journal-title":"Clin Exp Hypertens"},{"key":"e_1_2_1_148_2","first-page":"219","article-title":"Respiratory effects of labetalol in anginous or hypertensive patients","volume":"31","author":"Mazzola C","year":"1982","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_149_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.83.3.457"},{"key":"e_1_2_1_150_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198200433-00022"},{"key":"e_1_2_1_151_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb04832.x"},{"key":"e_1_2_1_152_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998009110080"},{"issue":"2","key":"e_1_2_1_153_2","first-page":"33","article-title":"Blood pressure, plasma volume, extracellular volume and glomerular filtration rate during treatment with labetalol in essential hypertension","volume":"56","author":"Rasmussen S","year":"1980","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_154_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1980.tb03705.x"},{"key":"e_1_2_1_155_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01225.x"},{"key":"e_1_2_1_156_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04767.x"},{"issue":"2","key":"e_1_2_1_157_2","first-page":"27","article-title":"Effect of propranolol and labetalol on renal haemodynamics at rest and during exercise in essential hypertension","volume":"56","author":"Pedersen EB","year":"1980","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_158_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.127"},{"key":"e_1_2_1_159_2","first-page":"634","article-title":"Effects of the long\u2010term administration of labetalol on blood pressure, hemodynamics and renal function in essential and renal hypertension","volume":"29","author":"Valvo E","year":"1981","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_160_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01900.x"},{"key":"e_1_2_1_161_2","first-page":"237","article-title":"Beta\u2010blockers and the kidney","volume":"8","author":"Epstein M","year":"1982","journal-title":"Mineral Electrolyte Metab"},{"key":"e_1_2_1_162_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1978.tb107854.x"},{"key":"e_1_2_1_163_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00618772"},{"key":"e_1_2_1_164_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(74)90283-X"},{"key":"e_1_2_1_165_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.40.1.14"},{"key":"e_1_2_1_166_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.40.1.35"},{"key":"e_1_2_1_167_2","first-page":"65","article-title":"Preliminary clinical trial on hypotensive and antiarrhythmic effect of labetalol","volume":"7","author":"Romano S","year":"1981","journal-title":"Drugs Exptl Clin Res"},{"key":"e_1_2_1_168_2","first-page":"613","article-title":"Acute antihypertensive and antiarrhythmic effects of labetalol","volume":"29","author":"Mazzola C","year":"1981","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_169_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197815040-00002"},{"key":"e_1_2_1_170_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01888.x"},{"key":"e_1_2_1_171_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01890.x"},{"issue":"3","key":"e_1_2_1_172_2","first-page":"751","article-title":"Labetalol in resistant hypertension","volume":"3","author":"Dargie HJ","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_173_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1980.tb135218.x"},{"issue":"2","key":"e_1_2_1_174_2","first-page":"57","article-title":"Effects of long\u2010term high\u2010dose labetalol on blood pressure in patients with severe hypertension resistant to previous therapy","volume":"56","author":"Kristensen BO","year":"1980","journal-title":"Postgrad Med J"},{"issue":"2","key":"e_1_2_1_175_2","first-page":"179s","article-title":"A multicentre open trial of labetalol in New Zealand","volume":"8","author":"New Zealand Hypertension Study Group.","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_176_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04770.x"},{"key":"e_1_2_1_177_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960050202"},{"issue":"3","key":"e_1_2_1_178_2","first-page":"737","article-title":"A double\u2010blind trial of labetalol","volume":"3","author":"Kane J","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_179_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01889.x"},{"key":"e_1_2_1_180_2","first-page":"1013","article-title":"Labetalol: potent antihypertensive agent that blocks both \u03b1\u2010 and \u03b2\u2010adrenergic receptors","volume":"123","author":"Milne BJ","year":"1980","journal-title":"Can Med Assoc J"},{"key":"e_1_2_1_181_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1979.tb119425.x"},{"key":"e_1_2_1_182_2","first-page":"118","article-title":"Combined trichlormethiazide and labetalol therapy in moderate to severe hypertension (abstract)","volume":"23","author":"Lifshitz AA","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_183_2","first-page":"204","article-title":"Labetalol with hydrochlorothiazide for moderate essential hypertension (abstract)","volume":"31","author":"Bloomfield S","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_184_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00548395"},{"issue":"3","key":"e_1_2_1_185_2","first-page":"743","article-title":"Labetalol in long\u2010term treatment of hypertension","volume":"3","author":"Prichard BNC","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_186_2","first-page":"213","article-title":"A pilot trial of labetalol (AH 5158A): a combined alpha and beta blocker in the treatment of hypertension","volume":"86","author":"Dent R","year":"1977","journal-title":"NZ J Med"},{"key":"e_1_2_1_187_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04774.x"},{"key":"e_1_2_1_188_2","first-page":"249","article-title":"Labetalol and pindolol in the treatment of hypertension: a comparative study","volume":"11","author":"Romo M","year":"1979","journal-title":"Ann Clin Res"},{"key":"e_1_2_1_189_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb00898.x"},{"issue":"2","key":"e_1_2_1_190_2","first-page":"69","article-title":"Labetalol and alprenolol. A comparative investigation of antihypertensive effect","volume":"56","author":"Kofod P","year":"1980","journal-title":"Postgrad Med J"},{"issue":"2","key":"e_1_2_1_191_2","first-page":"65","article-title":"Comparison of labetalol and propranolol in treatment of hypertension","volume":"56","author":"Harvald B","year":"1980","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_192_2","first-page":"516","article-title":"Pindolol and labetalol in hypertension: comparison of their antihypertensive effects with particular respect to conditions in the upright posture and during exercise","volume":"27","author":"Bjerle P","year":"1980","journal-title":"Curr Ther Res"},{"issue":"3","key":"e_1_2_1_193_2","first-page":"777","article-title":"Controlled comparison of labetalol and propanolol in the management of severe hypertension","volume":"3","author":"Pugsley DJ","year":"1976","journal-title":"Br J Clin Pharmacol"},{"issue":"665","key":"e_1_2_1_194_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.0954-6820.1982.tb00419.x","article-title":"Antihypertensive and metabolic effects of increasing doses of atenolol and labetalol. A comparative study in primary hypertension","author":"Nilsson OR","year":"1982","journal-title":"Acta Med Scand"},{"key":"e_1_2_1_195_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5694\/j.1326-5377.1978.tb112507.x","article-title":"Labetalol compared with pindolol plus hydralazine in the treatment of hypertension. A double\u2010blind cross\u2010over study","volume":"65","author":"Barnett AJ","year":"1978","journal-title":"Med J Aust"},{"key":"e_1_2_1_196_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1980.tb134775.x"},{"key":"e_1_2_1_197_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00542038"},{"key":"e_1_2_1_198_2","first-page":"71","article-title":"Antihypertensive effect and plasma levels of labetalol. A comparison with propranolol and dihy\u2010dralazine","volume":"17","author":"Lehtonen A","year":"1979","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"e_1_2_1_199_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb01081.x"},{"issue":"3","key":"e_1_2_1_200_2","first-page":"783","article-title":"Comparative anti\u2010hypertensive effects of labetalol and the combination of oxprenolol and phentolamine","volume":"3","author":"Johnson BF","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_201_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1980.tb134886.x"},{"key":"e_1_2_1_202_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04778.x"},{"key":"e_1_2_1_203_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04771.x"},{"key":"e_1_2_1_204_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00542319"},{"issue":"3","key":"e_1_2_1_205_2","first-page":"773","article-title":"A study of labetalol in patients of European, West Indian and West African origin","volume":"3","author":"Jennings K","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_206_2","first-page":"53","article-title":"Labetalol hydrochloride in the treatment of black and Indian hypertensive patients","volume":"25","author":"Seedat YK","year":"1979","journal-title":"Med Proc"},{"key":"e_1_2_1_207_2","first-page":"75","article-title":"Evaluation of labetalol hydrochlor (Trandate) in hospital outpatients","volume":"17","author":"Olivier LR","year":"1980","journal-title":"Clin Trials J"},{"key":"e_1_2_1_208_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04776.x"},{"key":"e_1_2_1_209_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01891.x"},{"key":"e_1_2_1_210_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1980.tb134776.x"},{"key":"e_1_2_1_211_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007997709110155"},{"key":"e_1_2_1_212_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04779.x"},{"key":"e_1_2_1_213_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01440.x"},{"key":"e_1_2_1_214_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04780.x"},{"issue":"3","key":"e_1_2_1_215_2","first-page":"305","article-title":"Acute effect of intravenous labetalol in the treatment of systemic arterial hypertension","volume":"3","author":"Ronne\u2010Rasmussen JO","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_216_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04781.x"},{"key":"e_1_2_1_217_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb01645.x"},{"key":"e_1_2_1_218_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01895.x"},{"key":"e_1_2_1_219_2","first-page":"47","article-title":"Diazoxide vs labetalol: a crossover comparison of short\u2010term effects in hypertension","volume":"3","author":"Rumboldt Z","year":"1983","journal-title":"Int J Clin Pharm Res"},{"key":"e_1_2_1_220_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1982.185"},{"key":"e_1_2_1_221_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01896.x"},{"key":"e_1_2_1_222_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6171.1121"},{"key":"e_1_2_1_223_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198005000-00030"},{"key":"e_1_2_1_224_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2044.1983.tb13984.x","article-title":"Labetalol in tetanus. The treatment of sympathetic nervous system overactivity","volume":"38","author":"Wesley AG","year":"1983","journal-title":"Anesthesia"},{"key":"e_1_2_1_225_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1978.tb107932.x"},{"key":"e_1_2_1_226_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1978.tb76817.x"},{"key":"e_1_2_1_227_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007997809111909"},{"key":"e_1_2_1_228_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1979.tb125802.x"},{"key":"e_1_2_1_229_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6191.672"},{"key":"e_1_2_1_230_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6089.737"},{"issue":"3","key":"e_1_2_1_231_2","first-page":"809","article-title":"Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol","volume":"3","author":"Rosei Agabiti E","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_232_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04769.x"},{"key":"e_1_2_1_233_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04786.x"},{"key":"e_1_2_1_234_2","first-page":"47","article-title":"Analgesic effect of peridural labetalol in the treatment of cancer pain","volume":"21","author":"Margaria E","year":"1983","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_1_235_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.280.6227.1300-a"},{"key":"e_1_2_1_236_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)90772-9"},{"key":"e_1_2_1_237_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.281.6236.387-a"},{"key":"e_1_2_1_238_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198200041-00002"},{"key":"e_1_2_1_239_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00618771"},{"key":"e_1_2_1_240_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6171.1122"},{"key":"e_1_2_1_241_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198100031-00006"},{"key":"e_1_2_1_242_2","unstructured":"CoevoetB LeulietP ComoyEet al.Labetalol for hypertension in pregnancy. Second Congress of the International Society for the Study of Hypertension in Pregnancy Cairo1980."},{"key":"e_1_2_1_243_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04783.x"},{"key":"e_1_2_1_244_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04784.x"},{"key":"e_1_2_1_245_2","doi-asserted-by":"publisher","DOI":"10.3109\/10641968009037147"},{"key":"e_1_2_1_246_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01901.x"},{"key":"e_1_2_1_247_2","first-page":"371","article-title":"Intravenous labetalol and dihydralazine in severe hypertension in pregnancy","volume":"1","author":"Garden A","year":"1982","journal-title":"Clin Exp Hypertens"},{"key":"e_1_2_1_248_2","first-page":"345","article-title":"A randomized comparison of methyldopa (Aldomet) and labetalol (Trandate) for the treatment of severe hypertension in pregnancy (abstract)","volume":"1","author":"Redman CWG","year":"1982","journal-title":"Clin Exp Hypertens"},{"key":"e_1_2_1_249_2","first-page":"223","article-title":"Fetal and neonatal cardiovascular effects of maternal labetalol therapy used in the treatment of pregnancy induced hypertension (abstract)","volume":"1","author":"Walker J","year":"1982","journal-title":"Clin Exp Hypertens"},{"key":"e_1_2_1_250_2","first-page":"146P","article-title":"Maternal administration of salbutamol and labetalol increases the amount of alveolar surfactant in lung of the day 27 foetal rabbit (abstract)","volume":"9","author":"Nicholas TE","year":"1978","journal-title":"Proc Aust Physiol Pharmacol Soc"},{"key":"e_1_2_1_251_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb01531.x"},{"key":"e_1_2_1_252_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1982.tb04719.x"},{"key":"e_1_2_1_253_2","first-page":"378","article-title":"Secretion of labetalol in breast milk of lactating women (abstract)","volume":"42","author":"Leitz F","year":"1983","journal-title":"Fed Proc"},{"key":"e_1_2_1_254_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)90366-X"},{"key":"e_1_2_1_255_2","unstructured":"JorgeCS.Labetalol in the hypertensive states of pregnancy I. Emergency treatment of severe hypertension in a pregnant patient. The European Society of Cardiology. Drug Symposium on Labetalol1979;131\u20134."},{"key":"e_1_2_1_256_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.281.6255.1635-b"},{"key":"e_1_2_1_257_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01224.x"},{"key":"e_1_2_1_258_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.48.4.364"},{"key":"e_1_2_1_259_2","first-page":"673P","article-title":"The effect of AH 5158, pindolol, propranolol, d\u2010propranolol on acute exercise tolerance in angina pectoris (abstract)","volume":"47","author":"Boakes AJ","year":"1973","journal-title":"Br J Pharmacol"},{"key":"e_1_2_1_260_2","first-page":"67","article-title":"Beneficial effect of labetalol in hypertensive patients with angina pectoris","volume":"63","author":"Lubbe WF","year":"1983","journal-title":"S Afr Med J"},{"key":"e_1_2_1_261_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04782.x"},{"key":"e_1_2_1_262_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(80)90354-3"},{"key":"e_1_2_1_263_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(81)90359-3"},{"key":"e_1_2_1_264_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01938.x"},{"key":"e_1_2_1_265_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04787.x"},{"key":"e_1_2_1_266_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01898.x"},{"key":"e_1_2_1_267_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01902.x"},{"issue":"3","key":"e_1_2_1_268_2","first-page":"817","article-title":"Cardiovascular effects of labetalol during halothane anaesthesia","volume":"3","author":"Scott DB","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_269_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04785.x"},{"key":"e_1_2_1_270_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/51.4.359"},{"key":"e_1_2_1_271_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1979.tb06260.x"},{"key":"e_1_2_1_272_2","first-page":"191","article-title":"The use of labetalol as a moderate hypotensive agent in otological operations \u2010 plasma concentrations after intravenous administration","volume":"18","author":"Kanto J","year":"1980","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_1_273_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1979.tb06304.x"},{"key":"e_1_2_1_274_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(79)90294-1"},{"key":"e_1_2_1_275_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6116.816-a"},{"key":"e_1_2_1_276_2","first-page":"987","article-title":"Cutaneous reactions to labetalol (letter)","volume":"1","author":"Finlay AY","year":"1978","journal-title":"Br Med J"},{"key":"e_1_2_1_277_2","first-page":"765","article-title":"Cutaneous reaction to labetalol","volume":"221","author":"Branford WA","year":"1978","journal-title":"Practitioner"},{"key":"e_1_2_1_278_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90974-6"},{"key":"e_1_2_1_279_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90534-7"},{"key":"e_1_2_1_280_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6112.580-a"},{"key":"e_1_2_1_281_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1979.tb13556.x"},{"key":"e_1_2_1_282_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.280.6207.115"},{"issue":"3","key":"e_1_2_1_283_2","first-page":"763","article-title":"Labetalol a new alpha and beta adrenoceptor blocking agent in hypertension","volume":"3","author":"Hansson L","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_284_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.282.6279.1824"},{"key":"e_1_2_1_285_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.55.646.567"},{"key":"e_1_2_1_286_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6188.496-d"},{"key":"e_1_2_1_287_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90255-X"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1983.tb03252.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1983.tb03252.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.1983.tb03252.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:40:28Z","timestamp":1761061228000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.1983.tb03252.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,7,8]]},"references-count":286,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1983,7,8]]}},"alternative-id":["10.1002\/j.1875-9114.1983.tb03252.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.1983.tb03252.x","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,7,8]]},"assertion":[{"value":"2012-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}